T1	Participants 0 10	Argatroban
T2	Participants 913 1151	Argatroban dose-dependently prolonged activated clotting time (ACT) with more patients reaching the minimum target ACT after the initial bolus injection (ARG250: 86.1%, ARG300: 89.5%, and ARG350: 96.8%) compared to 45.5% in UFH (p<0.001).
T3	Participants 1709 1719	Argatroban
